Financial Performance - The company reported revenue of HKD 13.6 million for the six months ended June 30, 2022, with a gross profit of HKD 5.9 million and a gross margin of 43.0%[5] - The consolidated loss attributable to the company's owners was HKD 2.4 million, a significant improvement from a loss of HKD 9.9 million in the previous year[5] - The company reported revenue of HKD 13,615,000 for the six months ended June 30, 2022, compared to no revenue in the same period of 2021[26] - Gross profit for the same period was HKD 5,859,000, with a cost of goods sold amounting to HKD 7,756,000[26] - The company incurred a loss before tax of HKD 2,436,000, a significant improvement from a loss of HKD 9,942,000 in the prior year[26] - Total comprehensive loss for the period was HKD 2,446,000, compared to HKD 9,942,000 in the previous year[26] - The company reported a net loss of HKD 2,400,000 for the six months ended June 30, 2022, compared to a loss of HKD 9,942,000 for the same period in 2021[37] - The net loss attributable to shareholders for the six months ended June 30, 2022, was HKD 2,446,000, a significant improvement from HKD 9,942,000 in the prior year[49] Assets and Liabilities - As of June 30, 2022, the total assets and net liabilities of the group were HKD 26.2 million and HKD 327.2 million, respectively[6] - The company had total assets of HKD 20,044,000 as of June 30, 2022, up from HKD 12,032,000 at the end of 2021[28] - The total assets as of June 30, 2022, amounted to HKD 26,217,000, an increase from HKD 19,115,000 as of December 31, 2021[43] - The total liabilities as of June 30, 2022, were HKD 353,392,000, compared to HKD 344,048,000 as of December 31, 2021[43] - Current liabilities increased to HKD 349,554,000 from HKD 267,372,000 year-over-year[28] - The company’s total equity attributable to owners was reported at HKD (319,592,000) as of June 30, 2022, reflecting accumulated losses[31] Cash Flow and Financing - The group's cash and bank balances were HKD 1.5 million, down from HKD 3.7 million as of December 31, 2021[6] - The net cash outflow from operating activities was HKD 5.1 million, compared to HKD 1.7 million in the previous year[6] - Cash and cash equivalents decreased by HKD 2,125,000 in the first half of 2022, with a closing balance of HKD 1,546,000 compared to HKD 372,000 at the end of June 2021[33] - The company has secured a loan financing of HKD 8,000,000 from an investor to cover operational costs and an additional HKD 12,000,000 to support business operations[38] - The company’s financing costs decreased to HKD 7,439,000 from HKD 8,236,000 year-over-year[26] - The total financing costs for the six months ended June 30, 2022, were HKD 7,439,000, down from HKD 8,236,000 in the same period of 2021[46] Business Operations and Strategy - The company is actively seeking new business opportunities to enhance long-term shareholder value despite challenges from the COVID-19 pandemic and geopolitical tensions[7] - There were no significant investments or major acquisitions and disposals during the reporting period[9] - The company continues to develop its medical and health lifestyle business to improve operational cash flow[38] - The company has one reportable segment, which is the distribution of medical equipment and products, consistent with the previous year[40] Employee and Governance - The total number of employees as of June 30, 2022, was 13, with compensation based on performance and market levels[14] - The company is committed to maintaining high standards of corporate governance, having complied with the relevant codes during the reporting period[23] - The company has not conducted any equity fundraising activities during the six months ended June 30, 2022[8] - The company has not granted any share options or share awards during the six months ended June 30, 2022[20][26] - The board believes that the company will have sufficient working capital to meet its financial obligations for the next twelve months, despite significant uncertainties[37] Revenue Breakdown - Revenue from the medical and health lifestyle business, specifically from the distribution of medical equipment and products, was HKD 13,615,000 for the six months ended June 30, 2022, a slight decrease from HKD 14,315,000 in 2021[39] - For the six months ended June 30, 2022, the total segment revenue was HKD 13,615,000, compared to a loss of HKD 9,942,000 for the same period in 2021[41] - The total segment performance for the six months ended June 30, 2022, was HKD 2,341,000, while the unallocated corporate expenses were HKD 2,339,000[41] Other Financial Information - Interest income from bank balances for the six months ended June 30, 2022, was HKD 1,000, while rental income increased to HKD 307,000 from HKD 62,000 in the previous year[44] - The weighted average number of ordinary shares for calculating basic and diluted loss per share remained constant at 326,037,000 shares for both periods[49] - The company did not recommend an interim dividend for the six months ended June 30, 2022, consistent with the previous year[48] - As of June 30, 2022, trade receivables were HKD 1,729,000, showing an increase from HKD 1,665,000 as of December 31, 2021[51]
京玖康疗(00648) - 2023 - 中期财报